Hims & Hers Health Inc. Stock News

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new injectable and oral testosterone replacement therapies (TRT) for eligible men. It's the largest expansion of the company's men's health program since first introducing the category last September, giving eligible men more options to treat low ...

Shares of Hims & Hers Health (HIMS) rose 5% on Tuesday after the telehealth company launched an online weight-management service for men in Germany, expanding its presence in Europe. The new offering allows patients to complete private online consultations and, if eligible, receive prescriptions from clinicians licensed in the European Union, along with ongoing support.

SYDNEY--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform, today announced the official launch of Hers in Australia, bringing its personalised care platform to women nationwide for the first time. The launch introduces first-of-their-kind treatment programs across Hair, Menopause and Perimenopause, and Weight Loss care - backed by women's-only research and 24/7 Care ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced Jon Franklin has joined the company as Chief Accounting Officer. Franklin, a CPA with two decades of technical accounting experience across public accounting and corporate controllership, will oversee the company's accounting organization, reporting to Chief Fi...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced two new clinical experts will join its global medical leadership team, led by Global Chief Medical Officer Pat Carroll, MD. Kultar Garcha, MD, will serve as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, will serve as ...

Grail's Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”).

Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in compounding and that it has already warned companies marketing unapproved retatrutide directly to consumers.